Morphotek(R) Inc., a privately held biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies, announces that the United States Food and Drug Administration (FDA) has granted orphan drug status to MORAb-009, a monoclonal antibody, for the indication of pancreatic cancer. [click link for full article]